Johnson and Johnson 2006 Annual Report Download - page 3

Download and view the complete annual report

Please find page 3 of the 2006 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

C H A I R M A N ’ S L E T T E R
Improving the health and well-being of
people around the world is a vital and
important business. It is perhaps the
world’s most meaningful business and, for
that reason, attracts exceptional people
who are capable, skilled, and possess a
genuine passion for making a difference
in people’s lives. As the world’s most
comprehensive and broadly based health
care company, Johnson & Johnson is
privileged to play a role in helping millions
of people be well . . . and stay well.
In 2006, thanks to the passion, hard work and ingenuity of our
people, we introduced hundreds of significant new products
and line extensions across the enterprise. Many advances
were discovered or invented by Johnson & Johnson scientists
and further developed by our R&D organizations. Among
them: new NEUTROGENA® and AVEENO® skin care products
featuring a patented breakthrough in long-lasting protection
against the sun’s harmful UVA rays . . . a new diagnostic test
from Veridex, LLC that allows doctors to know, during
breast cancer surgery, whether a woman’s cancer has spread
to her lymph nodes . . . new implant technology from
DePuy Orthopaedics, Inc. that enables adults previously
considered too young for hip replacement to preserve
bone and return to active lives . . . and a new medicine from
Tibotec Therapeutics Division of Ortho Biotech Products, LP
that offers hope to many treatment-experienced HIV patients
who thought they were running out of options.
And this is just a small sampling of the new products
introduced in 2006.
At the same time, our focus on growing our broad base in
human health care led to significant acquisitions across the
enterprise, including Pfizer Consumer Healthcare, which
solidified our position as the world’s premier consumer health
care company. Six key acquisitions in medical technology
further strengthened our position as the world’s largest and
“Thanks to the dedication of our people in advancing human
health and well-being, Johnson & Johnson delivered solid 2006
financial results while taking aggressive steps to position the
corporation for future growth.”
W I L L I A M C . W E L D O N
Chairman, Board of Directors, and Chief Executive Officer
N E T S A L E S
(in billions of dollars)
D I LU T E D E A R N I N G S PER S H A R E
(in dollars)
D I V I D E N D S PA I D PE R S H A R E
(in dollars)
C H A I R M A N ’ S L E T T E R
To Our
Shareholders
1
2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 62 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6
$36.3
$41.9
$47.3 $50.5 $53.3
$2.06 $2.29
$2.74
$3.35
$3.73
$0.795 $0.925
$1.095
$1.275
$1.455